Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Volastra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Volastra Therapeutics to Present Preclinical Data from KIF18A Inhibitor Program Targeting Chromosomally Unstable Tumors at FASEB Aneuploidy Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Volastra Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$1,130.0 million","upfrontCash":"$30.0 million","newsHeadline":"Volastra Therapeutics Announces Drug Discovery Collaboration with Bristol Myers Squibb","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Volastra Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Volastra Therapeutics","sponsor":"Polaris Partners","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Volastra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Volastra Therapeutics Announces First Patient Dosed in Phase I\/II Clinical Trial of VLS-1488, One in a Portfolio of Novel and Differentiated KIF18A Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Volastra Therapeutics","sponsor":"Function Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Function Oncology Announces Innovative Precision Medicine Partnership with Volastra Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Volastra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Volastra Therapeutics Announces First Patient Dosed in Phase Ib Clinical Trial of Sovilnesib","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Volastra Therapeutics

    Menu

    Volastra Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Volastra Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Volastra Therapeutics Announces First Patient Dosed in Phase Ib Clinical Trial of Sovilnesib

              Details:

              AMG-650 (sovilnesib) is a KIF18A inhibitor, small molecule drug candidate, which is being evaluated for the treatment of patients with platinum-resistant or refractory high-grade serous ovarian cancer.

              Lead Product(s): Sovilnesib

              Therapeutic Area: Oncology Product Name: AMG-650

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 16, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Volastra Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Function Oncology Announces Innovative Precision Medicine Partnership with Volastra Therapeutics

              Details:

              The collaboration brings together Function’s CRISPR-enabled personalized functional genomics technology with Volastra’s expertise in CIN to expand patient selection for Volastra’s KIF18A inhibitors, including VLS-1488, across an array of solid tumors indications.

              Lead Product(s): VLS-1488

              Therapeutic Area: Oncology Product Name: VLS-1488

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Recipient: Function Oncology

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership March 26, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Volastra Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Volastra Therapeutics Announces First Patient Dosed in Phase I/II Clinical Trial of VLS-1488, One in a Portfolio of Novel and Differentiated KIF18A Inhibitors

              Details:

              VLS-1488 is a potent, oral and clinical-stage KIF18A inhibitor with the potential to be the first-ever chromosomal instability-targeted cancer therapy.

              Lead Product(s): VLS-1488

              Therapeutic Area: Oncology Product Name: VLS-1488

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 30, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Volastra Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline

              Details:

              Under the terms of the licensing agreement, Volastra receives an exclusive worldwide license (ex-China) to develop and commercialize AMG650 (sovilnesib), an oral, first-in-class small molecule inhibitor of KIF18A.

              Lead Product(s): Sovilnesib

              Therapeutic Area: Oncology Product Name: AMG650

              Highest Development Status: Phase I Product Type: Small molecule

              Recipient: Amgen Inc

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement March 07, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Volastra Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline

              Details:

              The Funding will support clinical development of Volastra’s portfolio of KIF18A inhibitors including, AMG650 (sovilnesib), an oral, first-in-class small molecule, as well as advancement of a robust pipeline of research programs targeting chromosomally unstable cancers.

              Lead Product(s): Sovilnesib

              Therapeutic Area: Oncology Product Name: AMG650

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Polaris Partners

              Deal Size: $60.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing March 07, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Volastra Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Volastra Therapeutics to Present Preclinical Data from KIF18A Inhibitor Program Targeting Chromosomally Unstable Tumors at FASEB Aneuploidy Conference

              Details:

              Treatment with KIF18A inhibitor led to substantial, dose-dependent inhibition of tumor growth in multiple tumor models, with no effect on normal cells.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 09, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Volastra Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Volastra Therapeutics Announces Drug Discovery Collaboration with Bristol Myers Squibb

              Details:

              Under the terms of agreement, Volastra will be responsible for conducting activities for undisclosed targets. For select targets, Volastra will conduct all research activities through development candidate and BMS may take the responsibilities for all subsequent development.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Bristol Myers Squibb

              Deal Size: $1,130.0 million Upfront Cash: $30.0 million

              Deal Type: Collaboration March 21, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY